A recent study sought to investigate the overall survival (OS) advantage of the addition of trastuzumab to chemotherapy for patients with human epidermal growth factor 2-positive early breast cancer.
A recent study sought to investigate the overall survival (OS) advantage of the addition of trastuzumab to chemotherapy for patients with human epidermal growth factor 2- (HER2-) positive early breast cancer (EBC).
The researchers conducted a systematic literature review to identify randomized controlled trials and non-randomized studies that were published from January 1, 1990, to January 19, 2017. The review compared systemic therapies used in the neoadjuvant and adjuvant settings for the treatment of patients with HER2-positive EBC.
In total, the review identified 31 unique studies (28 randomized controlled trials and 3 non-randomized studies) that were included in the overall survival analyses. The included studies took place from 2008 to 2016. Cumulative network meta-analyses (cNMAs) of OS were conducted to assess the published literature over time. Using the cNMA approach allowed for a simultaneous comparison of multiple treatments that may not have been directly compared in the same study.
In total, 7341 patients (380 deaths) were included in the 2008 evidence network. By 2016, the number of patients included grew to 33,029 (3929 deaths). Based on the results from the reference case, cNMA, evidence in 2008 demonstrated an OS advantage for trastuzumab and chemotherapy compared with chemotherapy alone (hazard ratio [HR], 0.66; 95% CI, 0.03-12.27). The data showed that survival benefit strengthened over time, with an overall survival benefit in 2016 of HR 0.70 (95% CI, 0.62-0.82).
Overall, the researchers found that initial evidence in the reference case (randomized controlled trials alone) demonstrated that there was an OS advantage for trastuzumab/chemotherapy compared with chemotherapy monotherapy.
However, as additional OS data were published, the precision around the survival benefit became more notable over time. The researchers found that trastuzumab/anthracycline-containing chemotherapy and trastuzumab/non-anthracycline-containing chemotherapy provided similar OS advantages for patients with HER2-positive early breast cancer.
The study’s authors noted that these findings underscore why trastuzumab plus chemotherapy is the established standard of care in HER2-positive early breast cancer. Furthermore, the researchers found that the benefits of early patient access “far outweighed the risk of waiting for more precise information.”
Reference
Wilson F, Coombes M, Brezden-Masley C, et al. Herceptin (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis [published online November 14, 2018]. BMC. https://doi.org/10.1186/s13643-018-0854-y?rel=0" .
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.